5 years later - overview of the data collected in ACROSTUDY - different treatment regimens, database structure, basic strategies and safety.
AuthorsTrainer, Peter J
AffiliationP Trainer, Department of Endocrinology, Christie Hospital, Manchester, United Kingdom.
MetadataShow full item record
AbstractACROSTUDY is an observational registry intended to collect safety and efficacy data on pegvisomant therapy. 792 patients have been enrolled, of whom 83% had commenced pegvisomant prior to recruitment. The mean follow-up is 1.66 years with the mean duration of pegvisomant therapy 3.31 years representing 2625 patient years of treatment. 90% of patients were on once daily pegvisomant, and 67% were on monotherapy. Disappointingly IGF-I was normalised in less than 70% of patients, furthermore in 80% of patients with an elevated IGF-I the daily dose of pegvisomant was 20 mg or less. 56 Serious Adverse Events (SAEs) were reported, 13 of which were related to pegvisomant. 276 Adverse Events (AEs) were reported, of which 56 were considered related to pegvisomant. The AEs most frequently attributed to pegvisomant were disturbed liver function tests and injection site reactions. MRI imaging was available in 684 patients. 411 patients had at least one MRI on pegvisomant compared to a baseline. In 31 patients a decrease in tumour size has been reported, of whom 20 had previously received radiotherapy. An increase in tumour size has been reported and confirmed in 22 patients. In 11 patients there was contradictory data on tumour size, while in 6 patients central review of the films failed to confirm increase in tumour size. In conclusion the safety data are generally reassuring while the IGF-I normalisation rate is disappointing which probably reflects a failure of dose titration. Further effort is needed to understand the reasons for the failure of dose titration.
CitationACROSTUDY -5 years later - overview of the data collected in ACROSTUDY - different treatment regimens, database structure, basic strategies and safety. 2009: Eur. J. Endocrinol.
JournalEuropean Journal of Endocrinology
- The German ACROSTUDY: past and present.
- Authors: Buchfelder M, Schlaffer S, Droste M, Mann K, Saller B, Brübach K, Stalla GK, Strasburger CJ, German Pegvisomant Observational Study.
- Issue date: 2009 Nov
- Which patients with acromegaly are treated with pegvisomant? An overview of methodology and baseline data in ACROSTUDY.
- Authors: Brue T, Castinetti F, Lundgren F, Koltowska-Häggström M, Petrossians P, ACROSTUDY investigators.
- Issue date: 2009 Nov
- Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY.
- Authors: van der Lely AJ, Biller BM, Brue T, Buchfelder M, Ghigo E, Gomez R, Hey-Hadavi J, Lundgren F, Rajicic N, Strasburger CJ, Webb SM, Koltowska-Häggström M
- Issue date: 2012 May
- Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY.
- Authors: Freda PU, Gordon MB, Kelepouris N, Jonsson P, Koltowska-Haggstrom M, van der Lely AJ
- Issue date: 2015 Mar
- Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
- Authors: Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ, Lombardi G
- Issue date: 2006 Mar